

| Catalog No. | HW444046 |
|---|---|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Human |
| Isotype | IgG |
| Clone ID | HFB101110 |
| Biological activity | HFB101110 (0.01-10 nM) dose-dependently inhibits hCCL1-induced chemotaxis of CCR8 + cells [1]. HFB101110 (10 ug/mL) completely inhibits hCCL1-induced calcium flux in CCR8 + cells [1]. HFB101110 (0.3-300 ug/mL) does not induce significant cytokine release from healthy human PBMCs at concentrations up to 300 ug/mL [1]. HFB101110 exerts potent single-agent antitumor activity in a human CCR8 knock-in mouse model via depletion of intratumoral regulatory T cells [2]. HFB101110 is well-tolerated in wild-type mice [2]. HFB101110 is well-tolerated in cynomolgus monkeys [2]. |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | CKR-L1, CMKBR8, C-C CKR-8, GPR-CY6, CCR8, CMKBRL2, TER1, CCR-8, Chemokine receptor-like 1, CKRL1, CDw198, GPRCY6, C-C chemokine receptor type 8, CC-CKR-8, CC chemokine receptor CHEMR1 |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P51685 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | HFB101110 |
| Background | C-C chemokine receptor type 8 (CD198/CCR8) is a ~40 kDa protein. G protein-coupled receptor that can bind a variety of chemokines, such as CCL1, CCL8, CCL16, CCL18. Regulates monocyte and eosinophil chemotaxis. Undergoes internalization upon CCL18 binding, leading to induced migration and calcium flux of highly polarized Th2 cells. In microglial cells, promotes phagocytosis with CCL18 through NF-kappa-B and Src signaling pathways. Stimulation of the CCL1-CCR8 signaling axis protects the gut from acute intestinal damage. 1. Islam, SA. et al. (2013) The Journal of experimental medicine 210, 1889-98. PMID: 23999500 2. Ding, D. et al. (2022) Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 42, 19-28. PMID: 35041514 |
| References | 1. PRIGENT J, et al. Anti-ccr8 antibodies and uses thereof: U.S. Patent Application 18/685,068[P]. 2025-1-16. [HW444046] 2. Kumar R M, et al. Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors[J]. Cancer Research, 2022, 82(12_Supplement): 2899-2899. [HW444046] |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human CD198/CCR8 (HFB101110)




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский